KKKewon Kim

Kewon Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kewon Kim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure-Based Virtual Screening and De Novo Design Guided by 3D-QSAR Triage for the Identification of Nanomolar STK3 Inhibitors

    by Ahyoung Jang, Kewon Kim, Hyeonsoo Han, Ye Eun Kim, Taeho Kim, Kee-Choo Chung, Sungwoo Hong, Hwangseo Park

    Serine/threonine kinase 3 (STK3) is a core kinase in the Hippo signaling pathway that regulates cell proliferation, differentiation, and apoptosis. Dysregulation of this pathway is linked to various cancers and immune disorders, emphasizing STK3 as a promising therapeutic target for diseases that involve abnormal cell growth. Despite their therapeutic relevance, only a limited number of potent STK3 inhibitors have been reported, likely due to the difficulty in designing molecules that can bind tightly to the ATP-binding site of STK3. Using the 2-(2-amino-5-phenylpyrimidin-4-yl)-5-methoxyphenol (APPP) scaffold identified through virtual screening, we discovered a series of novel, potent STK3 inhibitors with half-maximal inhibitory concentration (IC50) values as low as 3.52 nM. This was made possible through an integrated molecular design strategy that combined structure-based de novo design with a predictive 3D-QSAR model to estimate IC50 values and prioritize compounds for synthesis. This approach improved the prioritization of compounds for synthesis by enhancing binding energy discrimination beyond the limitations of scoring functions in de novo design. Strategic derivatization at four defined positions on the APPP core enhanced interactions in the ATP-binding site of STK3, resulting in 18 of the 25 synthesized derivatives exhibiting IC50 values below 100 nM. These findings are particularly significant given the scarcity of known STK3 inhibitors with comparable potency, while also indicating that 3D-QSAR modeling contributed as a complementary triage tool rather than a standalone driver of lead discovery. This advancement stems from the use of quantum-mechanically derived 3D structural alignments and the incorporation of electrostatic potential distributions as quantitative molecular descriptors. Taken together, this study establishes a robust design paradigm for the rapid development of highly potent kinase inhibitors through structure-based computational strategies.

  • Polypharmacological Targeting of G2019S Mutant LRRK2 and JNK3 for the Discovery of a Lead Compound against Parkinson’s Disease

    by Kewon Kim, Taeho Kim, Hwangseo Park, Sungwoo Hong

    Parkinson's disease (PD) is a multifactorial neurodegenerative disorder for which single-target therapeutic strategies have shown limited success. To address this challenge, we pursued a structure-based polypharmacological approach targeting both the hyperactive G2019S mutant of leucine-rich repeat kinase 2 (LRRK2G2019S) and c-Jun N-terminal kinase 3 (JNK3), two kinases implicated in PD pathogenesis. Virtual screening, de novo design, and biological evaluation identified N2-phenyl-9H-purine-2,6-diamine (NPPD)-based scaffolds as promising dual-target hits. Subsequent macrocyclization and systematic structure-activity relationship optimization led to inhibitors with improved potency and drug-like properties. Among these, compound 17 exhibited low-nanomolar enzymatic inhibition against both kinases and exceptional picomolar cellular potency against LRRK2G2019S. While optimal cellular activity against JNK3 remains challenging, compound 17 demonstrated a favorable kinome-wide selectivity profile. Pharmacokinetic studies revealed excellent oral exposure, moderate clearance, and efficient brain penetration without observable toxicity. Overall, this study identifies a promising lead compound with significant potential as a therapeutic agent for PD.

  • Concurrent Optimizations of Efficacy and Blood–Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson’s Disease Therapeutics

    by Kewon Kim, Ahyoung Jang, Hochul Shin, Inhae Ye, Ji Eun Lee, Taeho Kim, Hwangseo Park, Sungwoo Hong

    The elevated activity of leucine-rich repeat kinase 2 (LRRK2) is implicated in the pathogenesis of Parkinson's disease (PD). The quest for effective LRRK2 inhibitors has been impeded by the formidable challenge of crossing the blood-brain barrier (BBB). We leveraged structure-based de novo design and developed robust three-dimensional quantitative structure-activity relationship (3D-QSAR) models to predict BBB permeability, enhancing the likelihood of the inhibitor's brain accessibility. Our strategy involved the synthesis of macrocyclic molecules by linking the two terminal nitrogen atoms of HG-10-102-01 with an alkyl chain ranging from 2 to 4 units, laying the groundwork for innovative LRRK2 inhibitor designs. Through meticulous computational and synthetic optimization of both biochemical efficacy and BBB permeability, 9 out of 14 synthesized candidates demonstrated potent low-nanomolar inhibition and significant BBB penetration. Further assessments of in vitro and in vivo effectiveness, coupled with pharmacological profiling, highlighted 8 as the promising new lead compound for PD therapeutics.